Fragile X Syndrome (FXS) is a genetic disease due to a CGG trinucleotide expansion, named full mutation (greater than 200 CGG repeats), in the fragile X mental retardation 1 gene locus Xq27.3; which leads to an hyper-methylated region in the gene promoter therefore silencing it and lowering the expression levels of the fragile X mental retardation 1, a protein involved in synaptic plasticity and maturation.
Epidemiology Insights
- The total cases of Fragile X Syndrome (FXS) in 7MM in 2017 was 117,962
- The gender-specific prevalent cases of Fragile X Syndrome (FXS) in the US in 2017
- 40,102 – Males
- 27,552 – Females
- The diagnosed prevalent cases of Fragile X Syndrome in the United States in 2017 was 67,654
- The prevalent population of FXS in Japan in 2017 was 12,645
Market Insight
Fragile X Syndrome market size in 7MM in 2017 was USD 33.8 Million
Fragile X Syndrome Market Drivers
- Funding and cooperation of various organizations
- Identifying potential targets by animal models
- Development of novel therapies
Fragile X Syndrome Market Barriers
- Failure of Clinical Trials
- Disease Burden
Key benefits of the report
1. Fragile X Syndrome market report covers a descriptive overview and comprehensive insight of the Fragile X Syndrome epidemiology and Fragile X Syndrome market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Fragile X Syndrome market report provides insights into the current and emerging therapies.
3. Fragile X Syndrome market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Fragile X Syndrome market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Fragile X Syndrome market.
Table of contents
1. Key Insights
2. Executive summary
3. Organisations
4. Fragile X Syndrome Epidemiology and Market Methodology
5. Fragile X Syndrome Market Overview at a Glance
6. Fragile X Syndrome Disease Background and Overview
7. Fragile X Syndrome Epidemiology and Patient Population
7.1. Key Findings
7.2. Total Diagnosed Prevalent cases of Fragile X Syndrome in 7MM
7.3. United States
7.4. EU5
7.5. Assumptions and Rationale
7.6. Germany
7.7. France
7.8. Italy
7.9. Spain
7.10. United Kingdom (UK)
7.11. Japan
8. Fragile X Syndrome Current Treatment
9. Unmet Need
10. Fragile X Syndrome Emerging Drugs
10.1. Key Cross Competition
10.2. Cannabidiol: Zynerba Pharmaceuticals
10.3. Acamprosate: Confluence Pharmaceuticals
10.4. BPN14770: Tetra Therapeutics
10.5. OV101: Ovid Therapeutics
10.6. Trofinetide: Neuren Pharmaceuticals
11. Fragile X Syndrome Market Size
12. Fragile X Syndrome Market Outlook: 7 MM
12.1. United States
12.2. EU5
12.3. Germany
12.4. France
12.4.3. Italy
12.5. Spain
12.6. United Kingdom
12.7. Japan
13. Market Drivers
14. Market Barriers
15. SWOT analysis
16. Cases studies
17. KOL Views
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/